Den Europæiske Union - svensk - EMA (European Medicines Agency)

mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiska medel - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

paranova läkemedel ab - tobramycin - lösning för nebulisator - 300 mg/5 ml - tobramycin 60 mg aktiv substans

Den Europæiske Union - svensk - EMA (European Medicines Agency)

mylan ire healthcare limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiska medel - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

Den Europæiske Union - svensk - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Den Europæiske Union - svensk - EMA (European Medicines Agency)

mylan s.a.s - ritonavir - hiv-infektioner - antivirala medel för systemisk användning - ritonavir är indicerat i kombination med andra antiretrovirala medel för behandling av hiv 1-infekterade patienter (vuxna och barn 2 år och äldre).

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

viatris limited - ezetimib - tablett - 10 mg - natriumlaurilsulfat hjälpämne; ezetimib 10 mg aktiv substans; laktosmonohydrat hjälpämne - ezetimib

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

viatris limited - kandesartancilexetil - tablett - 16 mg - mannitol hjälpämne; kandesartancilexetil 16 mg aktiv substans; laktosmonohydrat hjälpämne - kandesartan

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

viatris limited - kandesartancilexetil - tablett - 32 mg - kandesartancilexetil 32 mg aktiv substans; laktosmonohydrat hjälpämne; mannitol hjälpämne - kandesartan

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

viatris limited - kandesartancilexetil - tablett - 4 mg - laktosmonohydrat hjälpämne; mannitol hjälpämne; kandesartancilexetil 4 mg aktiv substans - kandesartan

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

viatris limited - kandesartancilexetil - tablett - 8 mg - kandesartancilexetil 8 mg aktiv substans; laktosmonohydrat hjälpämne; mannitol hjälpämne - kandesartan